Want to see SE:EKTA.B full AI Analyst Report?
Top Page
Elekta AB
(EKTA.B)
Select Model
Select Model
Rating:57Neutral
Price Target:
kr55.00
▼(-1.87% Downside)
Action:Reiterated
Date:08/28/26
The score is driven primarily by weakened financial performance (sharp revenue decline, recent losses, and higher leverage), partially offset by strong recent free cash flow generation. Technical indicators add moderate support due to positive momentum, while valuation is balanced between a negative P/E from losses and a relatively high dividend yield.
Positive Factors
Strong Free Cash Flow
Improved free cash flow provides internal funding for product development, service capacity and balance-sheet needs. Sustained cash generation can support resilience even while reported earnings remain under pressure.
Negative Factors
Sharp Revenue Contraction
The steep revenue decline signals weakened demand, project timing or execution across the business. Prolonged contraction would reduce operating leverage, constrain investment capacity and make recovery in profitability more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Free Cash Flow
Improved free cash flow provides internal funding for product development, service capacity and balance-sheet needs. Sustained cash generation can support resilience even while reported earnings remain under pressure.
Read all positive factors
Elekta AB (EKTA.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr19.98B
Dividend Yield4.37%
Average Volume (3M)1.09M
Price to Earnings (P/E)―
Beta (1Y)1.15
Revenue Growth-6.90%
EPS Growth-232.45%
CountrySE
Employees3,996
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.94
Shares Outstanding368,587,650
10 Day Avg. Volume1,551,960
30 Day Avg. Volume1,086,091
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.88
Price to Sales (P/S)1.22
P/FCF Ratio8.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr47.90Price Target Upside-14.54% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)4.06
Revenue Forecast (FY)kr17.22B
Elekta AB Business Overview & Revenue Model
Company Description
Elekta AB (publ) operates as a global medical technology company, delivering advanced clinical solutions for managing cancer and various brain disorders. Its extensive oncology offerings include sophisticated radiation therapy systems such as Vers...
How the Company Makes Money
Elekta primarily makes money by selling radiation therapy equipment and associated software to hospitals, cancer centers, and other healthcare providers. A major revenue stream comes from system sales (capital equipment such as linear accelerators...
Elekta AB Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
48
Neutral
Cash Flow
72
Positive
| Breakdown | TTM | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 16.61B | 16.72B | 18.02B | 18.12B | 16.87B | 14.55B |
| Gross Profit | 6.41B | 6.25B | 6.75B | 6.80B | 6.35B | 5.44B |
| EBITDA | 1.76B | 1.68B | 2.19B | 3.29B | 2.57B | 2.69B |
| Net Income | -362.00M | -520.00M | 237.00M | 1.30B | 943.00M | 1.15B |
Balance Sheet | ||||||
| Total Assets | 26.68B | 26.95B | 28.98B | 31.41B | 29.61B | 26.30B |
| Cash, Cash Equivalents and Short-Term Investments | 2.31B | 3.19B | 2.96B | 2.78B | 3.27B | 3.07B |
| Total Debt | 6.83B | 7.33B | 7.57B | 7.25B | 6.67B | 5.70B |
| Total Liabilities | 19.08B | 19.81B | 20.13B | 20.63B | 19.88B | 17.39B |
| Stockholders Equity | 7.56B | 7.10B | 8.80B | 10.78B | 9.73B | 8.91B |
Cash Flow | ||||||
| Free Cash Flow | 2.44B | 2.34B | 1.06B | 817.00M | 400.00M | 450.00M |
| Operating Cash Flow | 2.55B | 2.46B | 2.63B | 2.46B | 1.96B | 1.86B |
| Investing Cash Flow | -1.14B | -1.07B | -1.67B | -1.92B | -1.61B | -1.65B |
| Financing Cash Flow | -1.88B | -1.17B | -607.00M | -1.10B | -129.00M | -1.73B |
Elekta AB Technical Analysis
Negative
56.05
Price Trends
49.99
Positive
51.68
Negative
52.78
Negative
Market Momentum
0.53
Positive
47.51
Neutral
9.05
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:EKTA.B, the sentiment is Negative. The current price of 56.05 is above the 20-day moving average (MA) of 52.80, above the 50-day MA of 49.99, and above the 200-day MA of 52.78, indicating a neutral trend. The MACD of 0.53 indicates Positive momentum. The RSI at 47.51 is Neutral, neither overbought nor oversold. The STOCH value of 9.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:EKTA.B.
Elekta AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | kr2.61B | 27.92 | ― | ― | 8.40% | 0.74% | |
69 Neutral | kr2.07B | 28.44 | ― | 1.62% | 25.46% | 39.03% | |
57 Neutral | kr19.98B | -55.41 | -4.66% | 4.37% | -6.90% | -232.45% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | kr419.44M | -32.59 | ― | ― | 54.37% | 52.22% | |
42 Neutral | kr408.76M | -8.17 | ― | ― | -2.61% | -0.28% | |
41 Neutral | kr590.21M | -8.10 | ― | ― | ― | -23.57% |
* General Sector Average
SE:EKTA.B
Elekta AB
49.80
5.30
11.92%
SE:STIL
Stille AB
228.00
-2.00
-0.87%
SE:SUS
Surgical Science Sweden AB
50.20
-42.55
-45.88%
SE:OSSD
OssDsign AB
3.66
-12.05
-76.72%
SE:CLBIO
Corline Biomedical AB
16.20
1.60
10.96%
SE:FLUO
FluoGuide A/S
35.70
-4.50
-11.19%
Elekta AB Corporate Events
Elekta Delivers Strong Margin Gains Despite Q1 Revenue Dip
Aug 27, 2026
Elekta reported a 2 percent decline in first-quarter net sales in constant currencies, as solid growth in the Americas and Europe was offset by weaker performance in China, APJ and TIMEA. Despite softer revenue, orders grew 3 percent, driven by El...
Elekta Schedules First-Quarter 2026/27 Results Presentation for August 27
Aug 13, 2026
Elekta AB has invited analysts and investors to a presentation of its first-quarter 2026/27 results, scheduled for August 27 at 10:00 a.m. CEST, with the interim report to be published earlier that morning. Chief executive Jakob Just-Bomholt and c...
Elekta Calls 2026 AGM, Expands Voting Options for Shareholders
Jul 31, 2026
Elekta AB has called its shareholders to an Annual General Meeting to be held on September 3, 2026, at the company’s Stockholm headquarters, with registration starting half an hour before proceedings. Shareholders must be registered in Euroc...
Elekta Publishes 2025/26 Annual Report Focused on Precision Radiotherapy and Governance
Jul 3, 2026
Elekta AB has released its 2025/26 Annual Report, detailing its strategic framework, product portfolio, market environment and sustainability agenda as it seeks to make precision and adaptive radiotherapy accessible in everyday clinical care. The ...
Elekta Sets Mid‑Term Profitability Targets and 2026/27 Outlook Ahead of Capital Markets Day
Jun 17, 2026
Elekta has unveiled new mid‑term financial targets and a detailed outlook for fiscal 2026/27, outlining a strategy to boost profitability and long‑term growth through focused innovation, a new operating model and clearer regional strat...
Elekta Nomination Committee Proposes Board Line-up and New Director for 2026 AGM
Jun 12, 2026
Elekta’s Nomination Committee has proposed the re-election of nine current board members, including Chair Laurent Leksell, and the election of Sandvik CFO Cecilia Felton as a new director for the term ending at the next annual general meetin...
Elekta lifts margins and cash flow despite impairments and lower sales
May 28, 2026
Elekta reported a marginal 1% rise in full-year net sales at constant exchange rates, but a 7% decline in reported SEK sales, as emerging-market weakness offset growth in China and EMEA. Despite lower revenue and substantial non-cash impairments t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.